Advanced Enzyme Technologies Q1 FY27: Revenue Up 2%

Earnings snapshot and why it matters

Advanced Enzyme Technologies Ltd (NSE: ADVENZYMES) reported a softer start to FY27, even as consolidated revenue edged up year-on-year. For Q1 FY27 (quarter ended June 30, 2026), revenue from operations increased 2% YoY to INR 1,898 million. The quarter, however, saw a sequential decline, and profitability also came under pressure. Management attributed the performance to a challenging environment, costs such as power and fuel, and a temporary shift in mix. Alongside the operating update, the board approved a share buyback and the company moved to simplify its structure by buying the remaining stake in JC Biotech.

Revenue growth, but sequential decline

The company’s top line for the quarter stood at INR 1,898 million, up from INR 1,859 million in Q1 FY26, a rise of INR 39 million. Despite the YoY growth, revenue declined 7% compared to the previous quarter, as cited on the earnings call. A key factor highlighted was an additional INR 100 million sales reversal linked to revenue recognition timing. The company said the reversal had already been recorded by the time of the call. Management also indicated this impact is expected to reverse in Q2, based on its commentary in the event summary.

EBITDA and margins: pressure visible in the numbers

EBITDA for Q1 FY27 was INR 510 million, down 10% YoY from INR 564 million. On a sequential basis, EBITDA declined 19%, as stated in the summary. EBITDA margin slipped to 27% from 30% a year ago, a contraction of 300 basis points. Profit before tax (PBT) fell to INR 535 million from INR 549 million, a decline of INR 14 million, with PBT margin moving to 28% from 30%. Profit after tax (PAT) stood at INR 386 million versus INR 404 million last year, down 5% YoY, with PAT margin at 20%.

Segment performance: growth pockets and a drag

The quarter showed sharp divergence across business lines. The Bioprocessing segment delivered 30% YoY growth, driven by performance in the healthy food business. The Specialized Manufacturing segment reported 41% YoY growth, extending its momentum. In contrast, the Human Healthcare segment saw revenue decline 7% YoY due to lower pharma API sales. This mix of strong growth areas and weakness in healthcare shaped the overall outcome for the quarter.

US business remains challenged

Management flagged continued pressure in the US business during the call. The challenges were linked to geopolitical issues and a slow transition to branded products, as stated in the summary. This context is important because it suggests the revenue mix and near-term execution remain key variables. The company did not provide numerical guidance in the provided material, but it did specify the INR 100 million reversal as a timing issue. That disclosure helps explain why the quarter’s reported revenue may not fully reflect underlying demand in all lines.

Cost and mix factors behind the margin dip

The company cited elevated power and fuel costs as a factor affecting profitability. It also pointed to a temporary shift in sales mix that pressured margins during Q1. These factors, combined with the revenue recognition reversal, contributed to weaker operating leverage versus the previous year. The margin movement was visible not only in EBITDA but also in PBT and PAT margins. The quarter’s profitability metrics therefore reflected both cost-side stress and mix dynamics.

Buyback approval: size, price, and structure

The board approved a buyback of up to INR 697 million at a price not exceeding INR 500 per share. The buyback size was specified as up to 1,394,000 equity shares, representing 1.24% of the paid-up capital. The company framed the buyback as a signal of confidence in its value, as noted in the summary. Such actions typically matter to shareholders because they can support capital return and potentially reduce share count, although the actual impact depends on execution. The announcement also provided a clear ceiling price and maximum outlay.

JC Biotech becomes wholly owned

Advanced Enzyme Technologies also acquired the remaining 4.28% stake in JC Biotech. With this transaction, JC Biotech becomes a wholly-owned subsidiary. The company said the change helps streamline operations, according to the summary. While the financial impact was not quantified in the provided text, the strategic intent was stated as operational simplification. This step fits alongside the capital action as part of the quarter’s broader corporate update.

Key numbers at a glance

Segment trends captured in management summary

Call details and what investors will track next

The earnings conference call took place on August 12, 2026 at 04:00 PM IST for the quarter ended June 30, 2026. The company said an audio recording and transcript would be uploaded to its website in due course, and the audio recording was stated to be accessible on its investor relations page. Investor relations contact details were shared, including an email address: ir@advancedenzymes.com. Near-term attention is likely to remain on whether Q2 reflects the expected recovery from the INR 100 million sales reversal. Investors will also watch whether cost pressures moderate and if the US business transition to branded products progresses, as highlighted by management.